secwatch.observer — SEC 8-K summary
======================================

Issuer:     Royalty Pharma plc (RPRX)
CIK:        0001802768
Form:       8-K
Filed at:   2025-02-11T23:59:59+00:00
Accession:  0001193125-25-023988
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Royalty Pharma Q4 2024: Royalty Receipts +12% to $729M; 2025 guidance $2.9B–$3.05B
--------------------------------------------------------------------------------

- Portfolio Receipts $742M in Q4 (+1% YoY); FY 2024 $2,801M (-8% due to $525M Biohaven milestones in 2023).
- Net cash from operations $743M in Q4, $2,769M for FY. Adjusted EBITDA $669M (Q4), $2,565M (FY).
- 2025 Portfolio Receipts guidance $2,900M–$3,050M (+4–9% growth), excluding future transactions.
- Capital deployed $2.8B in 2024; new $3B share repurchase program authorized in Jan 2025, $2B planned in 2025.
- Acquisition of external manager RP Management for ~$1.1B in equity/cash/debt; expected Q2 2025 close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802768/000119312525023988/0001193125-25-023988-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802768/000119312525023988/d929959d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-023988

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer